This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesTrendsBuy This Stock About 23andMe Stock (NASDAQ:ME) Get 23andMe alerts:Sign Up Key Stats Today's Range$0.61▼$0.6150-Day Range$0.50▼$0.5052-Week Range$0.53▼$9.57VolumeN/AAverage Volume1.57 million shsMarket Capitalization$16.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. Read More Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ME Stock News HeadlinesThey sold your DNA after bankruptcy the 23andMe scandal nobody saw comingMay 7, 2026 | msn.comGodmother of Silicon Valley Esther Wojcicki, mother of the YouTube and 23andMe CEOs, shares her secret to raising future leadersApril 23, 2026 | msn.comBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited financials for 2024 and 2025 - a key step toward its Nasdaq uplisting. The company paired that move with a $40 million acquisition expanding its reach into hospitals and surgical centers, all within a $300M-plus addressable market. Zacks carries a $25.50 price target on the stock.May 12 at 1:00 AM | Huge Alerts (Ad)23andMe's Anne Wojcicki: Leaning into direct-to-consumerApril 15, 2026 | msn.comOzempic works better for some, new study finally suggests whyApril 10, 2026 | msn.comGenetic variations linked to weight loss, side effects from GLP-1 drugsApril 10, 2026 | reuters.comGenes May Predict How Much You’ll Lose on a Weight-Loss DrugApril 8, 2026 | wsj.comdna testingMarch 31, 2026 | yahoo.comSee More Headlines ME Stock Analysis - Frequently Asked Questions How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) issued its quarterly earnings results on Tuesday, January, 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative trailing twelve-month return on equity of 170.07% and a negative net margin of 183.39%. When did 23andMe's stock split? 23andMe's stock reverse split on the morning of Wednesday, October 16th 2024.The 1-20 reverse split was announced on Friday, October 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 23andMe own? Based on aggregate information from My MarketBeat watchlists, some other companies that 23andMe investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings1/28/2025Today5/12/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ME CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees770Year Founded2006Profitability EPS (Trailing Twelve Months)($15.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$666.70 million Net Margins-183.39% Pretax Margin-186.76% Return on Equity-170.07% Return on Assets-62.13% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio0.91 Sales & Book Value Annual Sales$208.78 million Price / Sales0.08 Cash Flow$0.65 per share Price / Cash Flow0.93 Book Value$2.34 per share Price / Book0.26Miscellaneous Outstanding Shares26,827,000Free Float19,766,000Market Cap$16.27 million OptionableNot Optionable Beta1.19 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ME) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersIran broke the petrodollar…For 50 years, every barrel of oil settled in dollars - that rule is what made the dollar the world's reserve c...Golden Portfolio | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayIn 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...Decentralized Masters | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
